Table 1.
Population characteristics for cohorts analysed in Scotland and Brazil
|
Scotland |
Brazil |
||||
|---|---|---|---|---|---|
| Two dose cohort | Vaccine effectiveness cohort* | Two dose cohort | Vaccine effectiveness cohort* | ||
| Total | 1 972 454 | 2 534 527 | 42 558 839 | 56 013 638 | |
| Sex | |||||
| Female | 997 890 (50·6%) | 1 269 011 (50·1%) | 23 006 854 (54·1%) | 29 683 170 (53·0%) | |
| Male | 974 564 (49·4%) | 1 265 517 (49·9%) | 19 551 985 (45·9%) | 26 330 468 (47·0%) | |
| Age, years | |||||
| Mean (SD) | 58 (15·3) | 52 (17·7) | 50 (14·0) | 48 (14·6) | |
| Median (IQR) | 57 (48–68) | 53 (40–63) | 51 (40–60) | 49 (38–59) | |
| 18–64 | 1 392 123 (70·6%) | 1 898 322 (74·9%) | 37 676 032 (88·5%) | 50 410 302 (90·0%) | |
| 65–79 | 376 286 (19·1%) | 411 685 (16·2%) | 3 355 384 (7·9%) | 3 816 360 (6·8%) | |
| ≥80 | 204 045 (10·3%) | 224 520 (8·9%) | 1 527 423 (3·6%) | 1 786 976 (3·2%) | |
| Vaccination month† | |||||
| Unvaccinated | .. | 503 455 (19·9%) | .. | .. | |
| December, 2020 | .. | 12 (0%) | .. | .. | |
| January, 2021 | 7 (<0·1%) | 221 953 (8·8%) | .. | 31 188 (0·1%) | |
| February, 2021 | 1587 (0·1%) | 546 523 (21·6%) | 523 (<0·1%) | 121 097 (0·2%) | |
| March, 2021 | 102 109 (5·2%) | 803 902 (31·7%) | 6290 (<0·1%) | 245 321 (0·4%) | |
| April, 2021 | 489 091 (24·8%) | 202 752 (8·0%) | 841 673 (2·0%) | 1 377 361 (2·5%) | |
| May, 2021 | 604 299 (30·6%) | 215 733 (8·5%) | 1 689 814 (4·0%) | 2 762 162 (4·9%) | |
| June, 2021 | 505 233 (25·6%) | 25 011 (1·0%) | 1 986 489 (4·7%) | 4 517 705 (8·1%) | |
| July, 2021 | 220 483 (11·2%) | 7994 (0·3%) | 8 786 235 (20·6%) | 14 003 567 (25·0%) | |
| August, 2021 | 34 689 (1·8%) | 3948 (0·2%) | 12 308 438 (28·9%) | 15 256 542 (27·2%) | |
| September, 2021 | 10 724 (0·5%) | 2548 (0·1%) | 12 113 808 (28·5%) | 12 717 568 (22·7%) | |
| October, 2021 | 4232 (0·2%) | 697 (<0·1%) | 4 825 569 (11·3%) | 4 981 127 (8·9%) | |
| Interval between doses, weeks | |||||
| Unvaccinated | .. | 503 455 (19·9%) | .. | .. | |
| One dose only | .. | 58 375 (2·3%) | .. | 13 014 057 (23·2%) | |
| <7 weeks | 27 121 (1·4%) | 27 122 (1·1%) | 292 142 (0·7%) | 292 508 (0·5%) | |
| 7–8 weeks | 360 728 (18·3%) | 360 796 (14·2%) | 952 852 (2·2%) | 957 090 (1·7%) | |
| 9–10 weeks | 1 020 620 (51·7%) | 1 020 637 (40·3%) | 4 106 531 (9·6%) | 4 134 102 (7·3%) | |
| 11–12 weeks | 492 722 (25·0%) | 492 727 (19·4%) | 25 419 256 (59·7%) | 25 649 224 (45·4%) | |
| ≥13 weeks | 71 263 (3·6%) | 71 416 (2·8%) | 11 788 058 (27·7%) | 11 966 657 (21·9%) | |
| Deprivation status quintile‡ | |||||
| 1 | 350 922 (17·8%) | 516 156 (20·4%) | 8 962 383 (21·1%) | 10 841 567 (19·4%) | |
| 2 | 382 783 (19·4%) | 506 194 (20·0%) | 8 034 607 (18·9%) | 10 042 918 (17·9%) | |
| 3 | 406 927 (20·6%) | 507 642 (20·0%) | 8 794 837 (20·7%) | 11 354 054 (20·3%) | |
| 4 | 412 754 (20·9%) | 495 809 (19·6%) | 8 570 045 (20·1%) | 11 531 844 (20·6%) | |
| 5 | 408 903 (20·7%) | 490 143 (19·3%) | 7 981 107 (18·8%) | 11 937 518 (21·3%) | |
| Unknown | 10 165 (0·5%) | 18 584 (0·7%) | 215 860 (0·5%) | 305 737 (0·5%) | |
| COVID-19 outcomes, n (rate per 100 000 person-years) | |||||
| COVID-19 hospital admission or death | 4662 (236·4) | 7211 (288·7) | 9039 (113·6) | 68 763 (318·0) | |
| COVID-19 hospital admission or death ≥14 days after second dose | 4494 (227·8) | .. | 6508 (101·8) | .. | |
| COVID-19 hospital admission | 4355 (220·8) | 6830 (273·4) | 8927 (110·8) | 68 494 (316·7) | |
| COVID-19 hospital admission ≥14 days after second dose | 4188 (212·3) | .. | 6436 (99·4) | .. | |
| COVID-19 death after second dose | 916 (46·4) | 1192 (47·7) | 3238 (40·7) | 21 973 (101·6) | |
| COVID-19 death ≥14 days after second dose | 911 (46·2) | .. | 2360 (37·0) | .. | |
| COVID-19 confirmed infection | 95 330 (4833·0) | 154 402 (6181·4) | 103 755 (1280·4) | 638 588 (2866·4) | |
| COVID-19 confirmed infection ≥14 days after second dose | 92 133 (4670·0) | .. | 74 974 (1158·1) | .. | |
Information about additional covariates is included within appendix 2 (pp 8–10).
Cohorts used to assess vaccine effectiveness differed between Scotland and Brazil: in Scotland, the availability of data on the entire unvaccinated population allowed analyses to be based on the resident adult population, whereas in Brazil, vaccine effectiveness was assessed among the cohort of individuals who had received at least one dose of ChAdOx1 nCoV-19.
Vaccine month is for the second dose for the rate ratio cohort and first dose for the vaccine effectiveness cohort.
Deprivation status was measured by quintiles of the Index of Multiple Deprivation 2020 for Scotland and Indice Brasileiro de Privacao at the municipality level for Brazil; 1 is the lowest quintile of deprivation, 5 is the highest quintile of deprivation.